Cardiac Safety: Ion Channel Screening Services
Medicinal chemists and toxicologists using the AVIVA
service can efficiently test compounds for potential
cardiac liability, using the in vitro hERG
electrophysiology assay and the cardiac sodium
channel Nav1.5 assay. AVIVA's screening services can
efficiently support medicinal chemistry programs by
testing hundreds of molecules per week.
hERG
HERGEXPRESS -The goal of this service is to provide our clients with reliable high quality data that can provide
clear guidance to their medicinal chemistry departments. Early assessment of the cardiac safety of compounds
can conveniently be established based on the output of the study report provided by AVIVA. In addition, experienced
electrophysiologists at AVIVA provide full support to assist customers who still have questions or specific
requests about the assay. AVIVA takes advantage of its proprietary hERG cell line for performing the in vitro
hERG electrophysiology assay. The hERG ion channel current is measured using the Sealchip technology and protocols
estensively validated over the course of several years and during the testing of over 3000 compounds.
(To see a set of hERG assay validation data, please click here)
GLP- The hERG assay is also avilable in GLP version for customers who need to present the data to
regulatory agencies. The GLP assay utilizes the AVIVA CHO-hERG cell line and the data are acquired
on a non-automated conventional electrophysiology station.
Nav1.5
Cardiac sodium channel - Inhibition of the inward sodium current is another potential mechanism by which pharmaceutical
compounds can induce arrhythmias. The Nav1.5 assay developed at AVIVA allows our clients to establish if their compounds
is a blocker of this important cardiac channel. (To see a set of Nav1.5 assay validation data, please click here)
For more ordering information please contact.
|
